[1]罗似亮　夏之柏.脑胶质瘤病人脑脊液Midkine表达的临床意义[J].中国临床神经外科杂志,2017,(06):416-418.[doi:10.13798/j.issn.1009-153X.2017.06.017]
　LUO Si-liang,XIA Zhi-bo..Clinical meanings of midkine expression in cerebrospinal fluid of patients with gliomas[J].,2017,(06):416-418.[doi:10.13798/j.issn.1009-153X.2017.06.017]
点击复制

脑胶质瘤病人脑脊液Midkine表达的临床意义()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
期数:
2017年06期
页码:
416-418
栏目:
论著
出版日期:
2017-06-25

文章信息/Info

Title:
Clinical meanings of midkine expression in cerebrospinal fluid of patients with gliomas
文章编号:
1009-153X（2017）06-0416-03
作者:
罗似亮　夏之柏
510080 广州，中山大学附属第一医院神经外科（罗似亮、夏之柏）
通讯作者：夏之柏，E-mail：xiazb12321@126.com
Author(s):
LUO Si-liang;  XIA Zhi-bo.
Department of Neurosurgery, The First Affiliated Hospital, Sun Ya t-sen University, Guangzhou 510080, China
关键词:
脑胶质瘤; 手术; 脑脊液; 中期因子
Keywords:
Gliomas;  Midkine;  Cerebrospinal fluid;  Meanings
分类号:
R 739.41; Q 786
DOI:
10.13798/j.issn.1009-153X.2017.06.017
文献标志码:
A
摘要:
目的 探讨人脑胶质瘤脑脊液中期因子（MK）水平与胶质瘤病理学的关系。方法 2015年5~10月手术治疗并经病理证实的胶质瘤25例，其中高级别胶质瘤（WHO Ⅲ~Ⅳ级）10例，低级别胶质瘤（WHO Ⅰ~Ⅱ级）15例。同期手术切除颅内良性肿瘤23例，非肿瘤性颅脑手术18例。酶联免疫吸附试验法检测所有病人术中以及脑胶质瘤术后腰椎穿刺术留取的脑脊液MK水平。免疫组化染色法分析胶质瘤组织MK表达水平。结果 胶质瘤组脑脊液MK浓度明显高于良性肿瘤组（P<0.001）和非肿瘤组（P<0.001），高级别胶质瘤脑脊液MK浓度显著高于低级别胶质瘤（P<0.05）；胶质瘤组织MK阳性程度与脑脊液MK的浓度呈显著正相关（r=0.75；P<0.001）。根据受试者工作特征曲线，脑脊液MK浓度>2.55 ng/ml区分胶质瘤和非肿瘤的敏感性和特异性分别为72.0%和83.3%。脑脊液MK浓度>2.11 ng/ml区分胶质瘤和良性肿瘤的敏感性和特异性为76.0%和82.6%。术后7~14 d，脑胶质瘤病人脑脊液MK水平[（2.22±1.23） ng/ml]显著下降（P<0.05）。结论 胶质瘤级别越高，肿瘤组织和脑脊液MK表达水平越高；切除肿瘤后脑脊液MK随之下降；脑脊液MK对术前诊断胶质瘤的具有较高的敏感性和特异性，同时对手术效果的评价也有重要意义。
Abstract:
Objective To investigate the expression of midkine (MK) in cerebrospinal fluid (CSF) and its relationship with clinicopathological features in patients with gliomas. Methods The level of MK in CSF were determined by enzyme linked immunosorbent assay in 25 patients with gliomas including WHO grades Ⅰ~Ⅱ gliomas (15 cases) and WHO grades Ⅲ~Ⅳ gliomas (10 cases), 23 patients with benign tumors and 18 patients with other lesions including communicating hydrocephalus (10 cases) and trigeminal neuralgia (8 cases). The MK expression were detected by immunohistochemical technique in 25 glioma patients after operative. Results The level of MK expression in CSF with gliomas was significantly higher in the patients with gliomas than those in the patients with benign tumors and non-neoplasms (P<0.001). The level [(7.02±4.62) ng/ml] of MK in CSF was significantly higher in the patients with WHO grades Ⅲ~Ⅳ gliomas than that [(3.20±1.84) ng/ml] in the patients with WHO grades Ⅰ~Ⅱ gliomas (P<0.05). The level of MK expression in CSF was positively related with that in the tumorous tissues in the patients with gliomas (r=0.751, P<0.001). The level of MK expression in CSF significantly declined from 7 to 14 days after the resection of tumors compared to that before the operation in the patients with gliomas (P<0.05). Conclusion It is suggested that the level of MK in CSF may be helpful to the diagnosis of human gliomas.

参考文献/References:

[1] Schwartzbaum JA, Fisher JL, Aldape KD, et al. Epidemio- logy and molecular pathology of glioma [J]. Nat Clin Pract Neurol, 2006, 2(9): 494-503.
[2] Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010 [J]. Neuro Oncol, 2013, 15(suppl 2): 1-56.
[3] Shimada H, Nabeya Y, Tagawa M, et al. Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma [J]. Cancer Sci, 2003, 94(7): 628- 632.
[4] Ikematsu S, Yano A, Aridome K, et al. Serum midkine levels are increased in patients with various types of carcinoma [J]. Br J Cancer, 2000, 83(6): 701-706.
[5] Tong Y, Mentlein R, Buhl R, et al. Overexpression of mid- kine contributes to anti-apoptotic effects in human menin- giomas [J]. J Neurochem, 2007, 100(4): 1097-1107.
[6] Cheng YP, Lin C, Lin PY, et al. Midkine expression in high grade gliomas: correlation of this novel marker with proli- feration and survival in human gliomas [J]. Surg Neurol Int, 2014, 5: 78.
[7] Ma J, Lang B, Wang X, et al. Co-expression of midkine and pleiotrophin predicts poor survival in human glioma [J]. J Clin Neurosci, 2014, 21(11): 1885-1890.
[8] Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system [J]. Acta Neuropathologica, 2007, 114(2): 97-109.
[9] Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression [J]. Cancer Sci, 2007, 98(5): 621-628.
[10] Muramatsu H, Shirahama H, Yonezawa S, et al. Midkine, a retinoic acid-inducible growth/differentiation factor: immu- nochemical evidence for the function and distribution [J]. Dev Biol, 1993, 159(2): 392-402.
[11] Jono H, Ando Y. Midkine: a novel prognostic biomarker for cancer [J]. Cancers, 2010, 2(2): 624-641.
[12] Cheng YP, Lin C, Lin PY, et al. Midkine expression in high grade gliomas: correlation of this novel marker with proli- feration and survival in human gliomas [J]. Surg Neurol Int, 2014, 5: 78.
[13] Zhu WW, Guo JJ, Guo L, et al. Evaluation of Midkine as a Diagnostic Serum Biomarker in Hepatocellular Carcinoma [J]. Clin Cancer Res, 2013, 19(14): 3944-3954.
[14] Meng ZW, Tan J, Zhang GZ, et al. Evaluation of serum midkine as a biomarker in differentiated thyroid cancer [J]. Life Sci, 2015, 130: 18-24.

相似文献/References:

[1]王振宇.脊髓髓内肿瘤诊断与治疗中若干问题的讨论[J].中国临床神经外科杂志,2015,(11):641.[doi:10.13798/j.issn.1009-153X.2015.11.001]
[2]黄　斌　李全才　张庭荣　郭运发　吴　昊　罗　坤.内镜 下与显微镜下经蝶手术治疗症状性Rathke囊肿的对比分析[J].中国临床神经外科杂志,2016,(05):264.[doi:10.13798/j.issn.1009-153X.2016.05.003]
　HUANG Bin,LI Quan-cai,ZHANG Ting-rong,et al.Surgery through transsphenoidal approach for symptomatic rathke cleft cysts: endoscopic surgery vs microsurgery[J].,2016,(06):264.[doi:10.13798/j.issn.1009-153X.2016.05.003]
[3]谢宝树　张　林　王　宇　贾　锋　殷玉华.复发性多发胶质母细胞瘤的预后分析[J].中国临床神经外科杂志,2016,(06):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
　XIE Bao-shu,ZHANG Lin,WANG Yu,et al.Analysis of prognoses in patients with recurrent multiple glioblastomas[J].,2016,(06):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
[4]陈正和　陈忠平.高级别胶质瘤的治疗现状及思考[J].中国临床神经外科杂志,2016,(06):350.[doi:10.13798/j.issn.1009-153X.2016.06.010]
[5]满明昊　李立宏　杨彦龙　李　敏　郭少春.颅脑损伤术后细胞免疫指标变化及脾多肽对其影响[J].中国临床神经外科杂志,2016,(06):362.[doi:10.13798/j.issn.1009-153X.2016.06.014]
　MAN Ming-hao,LI Li-hong,YANG Yan-yong,et al.Changes in peripheral cells immunity after operation and effect of spleen polypeptide on them in patients with traumatic brain injury[J].,2016,(06):362.[doi:10.13798/j.issn.1009-153X.2016.06.014]
[6]柯燕燕　周春霞　瞿建美　马丽萍.颞叶癫痫丙泊酚Wada试验中护理配合[J].中国临床神经外科杂志,2016,(06):380.[doi:10.13798/j.issn.1009-153X.2016.06.022]
[7]马　磊　张海红　郭　康　孙树凯　张　亮　贾　栋.神经导航辅助下手术治疗侧脑室脑膜瘤1例[J].中国临床神经外科杂志,2016,(04):255.[doi:10.13798/j.issn.1009-153X.2016.04.023]
[8]王亚平　贾晓雄　王　珺　王林林　谭溢涛　马德得　夏鹤春.神经内镜下与显微镜下经鼻蝶入路手术切除垂体腺瘤的疗效对比分析[J].中国临床神经外科杂志,2016,(03):145.[doi:10.13798/j.issn.1009-153X.2016.03.004]
　WANG Ya-ping,JIA Xiao-xiong,WANG-Jun,et al.Resection of pituitary adenomas by endoscopic and microscopic surgery via transnasal transsphenoidal approach: a comparative analysis[J].,2016,(06):145.[doi:10.13798/j.issn.1009-153X.2016.03.004]
[9]惠超杰　李文辉　曹立新　张广华.老年高血压小脑出血的小骨窗手术治疗[J].中国临床神经外科杂志,2016,(02):105.[doi:10.13798/j.issn.1009-153X.2016.02.016]
[10]赵建平　甘文芳　陈小奇　陈娇红　韩　琴　谢永香　张红波　孙彦辉.运动区脑肿瘤术后肢体功能障碍的康复护理[J].中国临床神经外科杂志,2016,(02):118.[doi:10.13798/j.issn.1009-153X.2016.02.023]
[11]李　林、吕扬成.脑胶质瘤手术前后凝血及纤溶指标的变化及其临床意义[J].中国临床神经外科杂志,2019,(07):396.[doi:10.13798/j.issn.1009-153X.2019.07.005]
　LI Lin,Lü Yang-cheng..Changes in perioperative coagulation and fibrolysis indexes in patients with brain gliomas and their clinical meanings[J].,2019,(06):396.[doi:10.13798/j.issn.1009-153X.2019.07.005]

备注/Memo

备注/Memo:
基金项目：国家自然科学基金（81072082）；和广东省科技计划项目（2013B021800245）
更新日期/Last Update: 2017-06-25